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Hypoxia-inducible factor-1 (HIF-1)–induced angiogenesis has been involved in numerous 
pathological conditions, and it may be harmful or beneficial depending on the types of 
diseases. Exploration on angiogenesis has sparked hopes in providing novel therapeutic 
approaches on multiple diseases with high mortality rates, such as cancer and ischemic 
stroke. The HIF-1 pathway is considered to be a major regulator of angiogenesis. HIF-1 
seems to be involved in the vascular formation process by synergistic correlations with 
other proangiogenic factors in cancer and cerebrovascular disease. The regulation 
of HIF-1–dependent angiogenesis is related to the modulation of HIF-1 bioactivity by 
regulating HIF-1α transcription or protein translation, HIF-1α DNA binding, HIF-1α and 
HIF-1α dimerization, and HIF-1 degradation. Traditional Chinese herbal medicines have a 
long history of clinical use in both cancer and stroke treatments in Asia. Growing evidence 
has demonstrated potential proangiogenic benefits of Chinese herbal medicines in 
ischemic stroke, whereas tumor angiogenesis could be inhibited by the active components 
in Chinese herbal medicines. The objective of this review is to provide comprehensive 
insight on the effects of Chinese herbal medicines on angiogenesis by regulating HIF-1 
pathways in both cancer and ischemic stroke.
Keywords: angiogenesis, herbal medicine, hypoxia-inducible factor-1, cancer, ischemic stroke
INTRODUCTION
Angiogenesis is the formation and remodeling of new blood vessels and capillaries from the existing 
vasculature through interaction among cellular matrix, cytokines, and proteases. It plays a pivotal role 
in diffusion exchange of metabolites and nutrients in all the tissues and organs of the human body 
(Shi, 2009; Kusumbe et al., 2014), occurring throughout our lives in both diseased and healthy states. 
Changes in metabolism result in proportional changes in angiogenesis and, therefore, proportional 
changes in capillarity. Oxygen is crucial for this process. Hypoxia occurs when there is reduced 
oxygen supply and/or increased oxygen demand. It is the principal physiological stimulus for inducing 
angiogenesis, which provides a stimulus-response pathway that tries to maintain adequate oxygenation 
in pathological status, such as tumor growth and ischemic stroke (Mengozzi et al., 2012; Brown, 2016). 
There has been great interest during the past decades in regulating angiogenesis as a therapeutic target 
for cancer and ischemic stroke. The current clinical application based on the principle of angiogenesis 
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includes antiangiogenic therapy and proangiogenic therapy. 
Antiangiogenic therapy has been used for cancer treatment, 
which inhibits the delivery of oxygen and nutrients to cancer cells. 
On the other hand, proangiogenic therapies in ischemic stroke 
could be beneficial by increasing blood flow. Hypoxia-inducible 
factor-1 (HIF-1), a regulator of essential adaptive responses to 
hypoxia-induced angiogenesis, is highly expressed under hypoxic 
conditions, such as aggressive tumors and ischemic brains (Sendoel 
et al., 2010; Berlow et al., 2017). HIF-1 has been suggested to be 
an important target in treating cancer and ischemic stroke by 
regulating the transcriptional activity of its downstream genes. 
The activity and accumulation of HIF-1α protein were found to 
be regulated at different levels, such as regulating HIF-1α synthesis 
stability or transactivation throughout its life cycle inside the cells 
(Yeom et al., 2011; Soleymani Abyaneh et al., 2017).
Traditional Chinese herbal medicine has a long history 
of clinical use in both cancer and stroke treatments in Asia. 
Chinese herbal medicines often use a variety of herbs in different 
complex combinations to enhance their therapeutic effects 
or reduce their toxicity. Growing evidence has demonstrated 
potential proangiogenic benefits of Chinese herbal medicines in 
ischemic stroke whereas tumor angiogenesis could be inhibited 
by the active components in herbal medicines (Hong et al., 2015; 
Gandin et al., 2016; Hong et al., 2016; Guo et al., 2018). Thus, the 
objective of this review is to provide comprehensive insight on 
how Chinese herbal medicines impact angiogenesis by regulating 
HIF-1 pathways in both cancer and ischemic stroke. In this study, 
we tried to give a systematic and timely update about the effects 
and mechanisms of several Chinese herbal medicines targeting 
HIF-1 pathways in cancer or ischemic stroke, such as Xue-Fu-
Zhu-Yu decoction, ginsenosides, Pien Tze Huang, Yi Ai Fang, 
baicalein, and curcumin. Their mechanisms of antiangiogenesis 
or proangiogenesis behaviors, potential toxicity, or side effects 
and future research directions were discussed.
METHOD
Both clinical trials and basic research on Chinese herbal 
medicines that target the HIF-1 pathway were included to 
assess their efficacy and underlying mechanisms. One Chinese 
database (China Journals Full-Text Database) and four English 
databases (AMED, MEDLINE, EMBASE, and The CENTRAL) 
were applied in our study to retrieve more recent publications on 
this topic. Chinese herbal medicines and their active compounds 
for ischemic stroke or cancer treatment will be included in this 
review paper if more than two research papers have described 
the in vitro and in vivo studies of the particular subject or of any 
paper describing clinical trials on the subject.
HYPOXIA-INDUCED ANGIOGENESIS
Hypoxia is the nonphysiological exposure to low oxygen tension of 
cells or tissues, which is associated with various pathological events, 
such as stroke, inflammation, and cancer. These pathological 
events induce the restoration of oxygen homeostasis by activating 
repair mechanisms such as angiogenesis. Hypoxia-induced 
angiogenesis includes several steps (Figure 1). 1) Exposure to 
FIGURE 1 | Schematic representation of the roles of vascular endothelial growth factor (VEGF), angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), matrix 
metalloproteinases (MMPs), and various growth factors during hypoxia-induced angiogenesis. The processes include upregulating the expression of proangiogenic 
factors; the synergistic effects of VEGF, Ang-1, and Ang-2 on angiogenesis; degrading the matrix components; new vessel formation; and stabilization, as described 
in detail in the text.
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low oxygen tension upregulates the expression of proangiogenic 
growth factors that activate their receptors (Sendoel et al., 2010; 
Berlow et al., 2017). 2) Vascular permeability increases in response 
to vascular endothelial growth factor (VEGF), thereby inducing 
the exudation of plasma proteins that form a primitive scaffold 
for migrating endothelial cells. Angiopoietin-1 (Ang-1) and 
angiopoietin-2 (Ang-2) exhibit antagonistic properties during the 
development of the vessel. Ang-1 is critical for vessel maturation, 
adhesion, migration, and survival, whereas Ang-2 is involved in 
vessel destabilization and promoting cell death. Yet, when it is in 
conjunction with VEGFs, Ang-2 can promote neovascularization 
(Jain and Carmeliet, 2012). The matrix metalloproteinases (MMPs) 
such as MMP2 and MMP9 can further induce angiogenesis by 
degrading matrix components (Ota et al., 2009; Kang et al., 2012). 
3) Proliferative endothelial cells assemble and form a lumen 
by migrating to a distant location (Nieuwenhuis et al., 2017). In 
this stage, several proteins can promote endothelial cell survival, 
adhesion, and migration, such as VE-cadherin and integrins 
αβ. After new vessels are formed, pericytes and smooth muscle 
cells will stabilize the walls and prevent leakage by surrounding 
the novel capillaries. Other factors including Ang-1 and platelet-
derived growth factor receptor (PDGFR) also take part in the 
maturation of novel capillaries (Rivera and Bergers, 2014).
Hypoxia-induced angiogenesis shows significant differences 
in signal pathways compared with physiological angiogenesis. For 
example, physiological angiogenesis in embryonic development 
requires activating the VEGF pathway, whereas hypoxia-
induced angiogenesis such as tumor angiogenesis can also 
induce angiogenesis by recruiting myeloid cells and upregulate 
alternative vascular growth factors in addition to VEGF, such 
as fibroblast growth factor (FGF) and placental growth factor 
(PlGF). Although postischemic tissue revascularization is crucial 
for recovery in brain tissues after ischemic stroke (Li Q. et al., 
2018) or in the heart after myocardial infarction (Chen R. et al., 
2018), the activation of angiogenesis is harmful in disorders such 
as macular degeneration and cancer (Pio et al., 2013). Therefore, 
there is great interest in regulating angiogenesis as a possible 
therapeutic method for different kinds of diseases. Elucidating 
the molecular mechanism of hypoxia-induced angiogenesis will 
help in the identification of potential therapeutic targets and 
improve therapeutic effects.
HYPOXIA-INDUCIBLE FACTOR-1
Changes in oxygen supply represent a pivotal physiological stimulus 
for all eukaryotic cells that require adequate oxygen consumption 
for intracellular metabolic reactions. In addition to its contribution 
to the maintenance of intracellular bioenergetics by producing 
mitochondrial ATP, O2 also serves as a universal electron acceptor 
in various biochemical pathways. Therefore, genes involved in 
responding to hypoxia are highly conserved during evolution. 
HIF-1 is an oxygen-dependent transcriptional activator, which is 
composed of HIF-1α, the alpha subunit, and the aryl hydrocarbon 
receptor nuclear translocator (Arnt), the beta subunit. Both 
subunits belong to the bHLH-PAS (Per/Arnt/Sim) family. HIF-1 
is induced in hypoxic cells and binds to the cis-acting hypoxia 
response element (HRE) of the human EPO gene, which is required 
for erythropoietin synthesis (Aldo and Elisabetta, 2018; Zhu and 
Zhang, 2018). Intracellular oxygen concentration levels can affect 
the subcellular localization and protein activity of the HIF-1α 
subunit, whereas the expression of HIF-1β is not regulated by the 
oxygen level (Wang et al., 2018). The HIF-1α and HIF-1β subunits 
are similar in structure, and both contain two PAS domains. The 
bHLH and PAS domains are critical for the heterodimer formation 
of HIF-1α and HIF-1β and for DNA binding. The HIF-1α subunit 
contains N-terminal transactivation domains (TAD-N) and 
C-terminal transactivation domains (TAD-C) concatenated by an 
inhibitory domain (Figure 2). The TAD-N is continuous with protein 
stability that overlaps with the oxygen-dependent degradation 
(ODD) domain. The TAD-C is independent of protein stability that 
interacts with p300/CBP and is critical for transcription activity. The 
HIF-1α protein is unstable (half-life = 5 min) and is modified by 
various posttranscriptional regulations, including phosphorylation, 
hydroxylation, ubiquitination, acetylation, and nitrosation. Factor 
inhibiting HIF-1 (FIH-1) hydroxylates asparagine-803 of HIF-1α 
within the TAD-C under normoxic conditions, which inhibits 
the interaction of HIF-1α with transcriptional coactivators. The 
molecular mechanisms of the pivotal role of HIF-1 in the regulation 
of angiogenesis have been revealed in recent years. Recent studies 
have demonstrated that HIF-1 activity in human tissues can 
induce angiogenesis in the following ways: 1) by activating the 
transcription of various angiogenic genes or their receptors such 
as ANGPT1, ANGPT2, VEGF, PlGF, and PDGFB (Chen et al., 
2017); 2) by modulating proangiogenic chemokines and receptors 
(SDF-1α, sphingosine-1-phosphate, stromal cell–derived factor 1α, 
receptor CXCR4, sphingosine-1-phosphate receptors, and C-X-C 
chemokine receptor type 4), thus promoting the recruitment of 
endothelial progenitor cells to the hypoxic site (Soni and Padwad, 
2017); and 3) by facilitating cell cycle progression and DNA 
replication in endothelial cells (Toth and Warfel, 2017). Through 
the phosphoinositide 3-kinase (PI3K) or Ras/MAPK pathway, 
several growth factors and their cognate receptors can influence 
cellular responses to hypoxia and regulate the expression of 
HIF-1α. Previous studies have shown that inhibition of PI3K 
pathway downregulates both basal and mitogen-induced HIF-1α 
expression (Cheng et al., 2018). In general, the modifications of 
HIF-1 are rapidly and precisely regulated according to the cellular 
oxygen concentration by multiple signaling. The hypoxia-induced 
angiogenesis is a highly complex and orchestrated process in 
human disease. HIF-1 was found to be a major modulator of 
hypoxia-induced angiogenesis by synergistic correlations with 
various proangiogenic factors and regulates many genes that play 
important roles in angiogenesis (Table 1). Thus, HIF-1 modulation 
could offer therapeutic benefits for various hypoxia pathologies, 
including diseases with high mortality and morbidity rates, such as 
cancer and ischemic stroke.
HYPOXIA-INDUCED ANGIOGENESIS IN 
CANCER AND THE ROLE OF HIF-1
Because of the expansive growth activities within malignant 
tumor, cancer cells are highly metabolic. However, the poorly 
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vascularized original tissue structure leads to inadequate oxygen 
supply for tumor progression. Hypoxia is commonly observed in 
the microenvironment of cancer, which arises in cancer via the 
uncontrolled proliferation driven by the oncogene of cancer cells 
in the absence of an efficient vascular bed. As a result of rapid 
cell proliferation, the cancer cell quickly exhausts the oxygen 
supply and nutrient from the normal vasculature, which leads to 
hypoxia. In previous studies, the relationship between hypoxia and 
tumor progression has been proven by O2-sensitive microsensors 
(Semenza, 2003; Bohonowych et al., 2011). Clinical studies have 
shown that patients with hypoxic cervical tumors, head and neck 
cancer, and sarcoma of soft tissue may have worse disease-free 
survival than that of patients with normally aerated tumors. The 
inadequate oxygen supply at the tumor tissue may induce tumor 
progression through selective pressure by the mutation of cancer 
suppressor genes, which may reduce tumor cells’ apoptotic capacity 
and promote tumor growth. Another key characteristic of the 
hypoxic response in tumor is the modulation of multiple genes that 
promote angiogenesis to fortify oxygen supply (Zagzag et al., 2000).
Cancer growth and metastasis depend on lymphangiogenesis 
and neovascularization triggered by hypoxia signals from cancer 
cells. Cancer cells under hypoxic conditions will upregulate the 
expression of PDGF, Ang-2, stromal-derived factor 1 (SDF-1), and 
VEGF, which are crucial in endothelial cell activation and promoting 
neoangiogenesis. Activated HIF-1 plays a crucial role in hypoxia-
adaptive responses of the tumor cells through transcriptional 
FIGURE 2 | HIF-1α gene structure, stability, and activation. (A) Normal oxygen level induces the degradation of HIF-1α by hydroxylation or acetylation-mediated VHL 
binding and also transcriptional activity of HIF-1α. (B) Under hypoxic conditions, VHL is not prolyl-hydroxylated and cannot bind to HIF-1α protein, which leads to a 
decreased rate of HIF-1α degradation. Hypoxia promotes the interaction of HIF-1α within CBP/p300 and induces dimerization of HIF-1α with HIF-1β, which results in 
HIF-1 transcription factor formation. The active HIF-1 will further bind to HREs and activate the transcription of downstream genes.
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activation of these proangiogenesis genes. As shown in previous 
studies, HIF-1 can mediate acute hypoxia-induced VEGF expression 
in neuroblastoma, whereas HIF-2 modulates VEGF expression 
during prolonged hypoxia (Maxwell et al., 1999). Furthermore, 
VEGF expression under hypoxia may increase the activity of other 
proangiogenic factors and their receptors; thus, vessel outgrowth 
was stimulated through multiple factors. This so-called “angiogenic 
switching” induces tumor angiogenesis and stimulates tumor 
growth by supplying nutrients and oxygen by newly formed vessels 
(Singh et al., 2017). During the cellular adaptation to hypoxic stress, 
PI3K/AKT/mTOR and MAPK signaling pathways are involved in 
hypoxia-induced tumor angiogenesis by various growth factors 
that bind to toll-like receptors (TLRs), alarmin receptors, receptor 
tyrosine kinases, and G protein–coupled receptors on cell surface, 
which may also activate HIF-1 (De Francesco et al., 2018). The 
mitogen-activated protein kinase (MAPK) and PI3K pathways 
are activated by the combination of growth factor with its cognate 
receptor tyrosine kinase. PI3K promotes the activation of the 
downstream mammalian target of rapamycin (mTOR) and serine/
threonine kinase AKT. mTOR further induces p70 S6 kinase (S6K) 
and its substrate phosphorylation then induces HIF-1α protein 
synthesis. In the MAPK pathway, the extracellular signal-regulated 
kinase (ERK) is activated by the upstream signal cascade (RAS/
RAF/MEK). Activated ERK promotes the phosphorylation of 
eukaryotic translation initiation factor 4E (eIF-4E) binding protein 
(4E-BP1) and MAP kinase interacting kinase (MNK). MNK can 
also phosphorylate eukaryotic translation initiation factor 4E 
(eIF-4E) directly. Then, the HIF-1α mRNA translation is activated 
(Rius et al., 2008; Ban et al., 2017; Aldo and Elisabetta, 2018). 
Key cellular responses to the hypoxic tumor microenvironment 
TABLE 1 | Angiogenesis-Related Genes That Are Transcriptionally Activated by HIF-1.
Target Gene Protein Name Roles in Angiogenesis Reference
c-MET c-mesenchymal-epithelial transition Promotes endotheliocyte motility and vascular 
formation
(Matteucci et al., 2003)
LRP1 Low-density lipoprotein receptor-
related protein 1
Regulates vascular integrity (Woodley et al., 2009; Li et al., 2014)
HO-1 Heme oxygenase-1 Regulates vascular tone and blood pressure (Sato et al., 2012; Mathew and Sarada, 2018)
GPI Glucose-6-phosphate isomerase Tumor-secreted cytokine that stimulates vascular 
endothelial cell motility
(Zdralevic et al., 2018)
MIC2 CD99 antigen Inhibits cell-extracellular matrix adhesion and 
promotes vascular remodeling
(Ohradanova et al., 2008; Llurba et al., 2014)
VEGF Vascular endothelial growth factor Stimulates the formation of blood vessels (Al-Anazi et al., 2018; Fortenbery et al., 2018; 
Prangsaengtong et al., 2018)
EG-VEGF Endocrine gland–derived vascular 
endothelial growth factor
Angiogenic growth factor specifically expressed in 
the ovaries
(Su et al., 2014; Mi et al., 2018)
ENG Endoglin Regulates transforming growth factor-β–dependent 
vascular remodeling and angiogenesis
(Bluff et al., 2009; Tal et al., 2010)
ET1 Endothelin 1 Regulates vascular tone and blood pressure (Kaul et al., 2013; Ambrosini et al., 2015; Belaidi 
et al., 2016)
LEP Leptin Has mitogenic activity on vascular endothelial cells 
and plays a role in matrix remodeling by regulating 
the expression of matrix metalloproteinases (MMPs) 
and tissue inhibitors of metalloproteinases (TIMPs)
(Al-Anazi et al., 2018; Rausch et al., 2018)
TGF-β3 Transforming growth factor beta 3 Regulates angiogenesis in the developing brain via 
paracrine signaling to vascular epithelial cells
(Taheem et al., 2018; Tsai et al., 2018)
α1β-AR α1β-adrenergic receptor Activates vascular epithelial cell proliferation (Park et al., 2011; Forbes et al., 2016)
ADM Adrenomedullin Regulates vascular tone and blood pressure (Sena et al., 2014; Matsumoto et al., 2018)
NOS2 Nitric oxide synthase 2 Regulates vascular tone and blood pressure (Magierowski et al., 2018; Pena-Mercado et al., 
2018; Suvanish Kumar et al., 2018)
TFF Intestinal trefoil factor Regulates vascular epithelial restitution (Miki et al., 2004; Manresa and Taylor, 2017)
MMP2 Matrix metallopeptidase 2 Regulates vascular patterning and branching (Sharma et al., 2018; Tyszka-Czochara et al., 
2018)
PDGFβ platelet-derived growth factor 
receptor-β 
Maintains vascular stability (Beppu et al., 2005; Gramley et al., 2010; Hsu 
et al., 2014)
FN1 Fibronectin 1 Promotes vascular remodeling (Kondisetty et al., 2018; Zeinali et al., 2018)
PAI-1 plasminogen activator inhibitor-1 Promotes vascular remodeling (Kabei et al., 2018; Peterle et al., 2018; Toullec 
et al., 2018)
UPAR Urokinase-type plasminogen activator 
receptor 
Regulates growth factor activation; promotes ECM 
and vascular remodeling
(Carroll and Ashcroft, 2006; Laurenzana et al., 
2017)
P4H (I) prolyl-4-hydroxylase (i) Regulates vascular collagen production (Trollmann et al., 2018)
ANGPT2 Angiopoietin-Tie2 Regulates vascular remodeling (Yamakawa et al., 2004; Trollmann et al., 2018)
KRT19 keratin-19 responsible for the structural integrity of vascular ECs (Copple, 2010)
KRT14 keratin-14 Responsible for the structural integrity of vascular 
ECs
(Pahlman et al., 2015)
KRT18 keratin-18 Responsible for the structural integrity of vascular 
ECs
(Muller et al., 2018)
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triggered by HIF-1 and its downstream targets increase the vascular 
formation, cancer invasiveness, and resistance to treatment (Liu H. 
et al., 2018).
Hypoxia-induced tumor angiogenesis is stimulated and 
regulated by both activator and inhibitor molecules. However, 
simple upregulation of the activity of proangiogenesis factors 
is not sufficient for neovascularization of the tumor. Negative 
regulators or endogenous inhibitors of vessel growth also 
need to be downregulated, such as the thrombospondin-1 and 
thrombospondin-2. In recent years, various anticancer agents have 
been developed by targeting these angiogenic activator or inhibitor 
molecules in malignant tumor. A number of antiangiogenesis drugs 
have been approved by the U.S. Food and Drug Administration 
(FDA) for treating progressive cancer. So far, most of these drugs 
are molecular targeted agents that were developed specifically to 
target VEGF or its receptors, such as bevacizumab (Avastin) and 
vandetanib (Caprelsa) (Li et al., 2018a). During the last two decades, 
interest in the role of HIF-1 in tumor angiogenesis has grown 
exponentially since its identification and molecular characterization 
in human cancer. Much progress has been made recently about the 
cellular and molecular mechanism of HIF-1 and its involvement in 
cancer growth and metastasis based on the analysis of experimental 
animal models and human cancer biopsies.
In brief, activation of HIF-1 in cancer cells is one of the key 
masters orchestrating their adaptation mechanism to the hypoxic 
conditions. Considering the pivotal roles of HIF-1 in tumor 
angiogenesis, there has been great interest in developing novel 
anticancer agents inhibiting the related pathway. As we know, 
HIF-1 modulation in cancer cells is a complex network including 
various signal cascades and overlapping mechanisms, each of 
which might act as a potential target to selectively intervene cancer.
CHINESE HERBAL MEDICINES 
MEDIATE ANTIANGIOGENIC FACTORS 
BY REGULATING HIF-1 PATHWAYS IN 
CANCER TREATMENT
The use of Chinese herbal medicines to treat cancer dates back 
centuries in ancient traditional folklore in China and Asian 
countries (Qin et al., 2018; Oyenihi and Smith, 2019). Many 
herbal extracts and herbal soups have been reported that could 
relieve clinical symptoms, improve quality of life, and reduce 
side effects in cancer therapy (Dong et al., 2010; Xu et al., 2014; 
Tian et al., 2010). In view of the importance of HIF-1 in tumor 
angiogenesis, the development of herbal medicine inhibitors 
for this pathway has attracted wide interest. It is clear that 
the regulation of HIF-1 is a highly complex network cascade 
and overlapping mechanisms involving multiple targets and 
signaling pathways, such as HIF-1α mRNA expression, HIF-1α 
protein expression, and HIF-1 transcriptional activity. As shown 
in Figures 2 and 3, we have concluded that Chinese herbal 
FIGURE 3 | Chinese herbal medicines inhibit the activation of the HIF-1 pathway in cancer treatment through different targets.
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medicines can regulate HIF-1 by targeting different targets that 
exert antiangiogenic effects in cancer therapy.
Inhibitors of HIF-1α mRNA and/or Protein 
Expression
Numerous herbal medicines that inhibit HIF-1α mRNA and/
or protein expression have significant antiangiogenic effects. 
Berberine, the main active ingredient isolated from Coptis 
chinensis, has been shown to decrease the expression of HIF-1α 
and VEGF in esophageal cancer, hepatocellular carcinoma, 
prostate cancer, nasopharyngeal carcinoma, and lung cancer 
(Fu et al., 2013; Yang et al., 2013; Tsang et al., 2015; Zhang 
et  al., 2014a; Zhang C. et al., 2014). Isoliquiritigenin, a natural 
product derived from liquorice, could significantly decrease 
VEGF expression by promoting HIF-1α degradation in breast 
cancer cells (Wang et al., 2013). Ginsenoside Rg3 is one of 
the active ingredients in ginseng. Chen et al. (2010) reported 
that ginsenoside Rg3 could inhibit VEGF expression through 
downregulation of HIF-1α protein in various human cancers. 
Wang et al. (2009) reported that ginsenoside Rg3 could inhibit 
HIF-1α and VEGF expression during hypoxia and inhibit 
hep-2 cell growth by affecting cell cycle progression. Another 
report has shown that 20(R)-ginsenoside Rg3 could inhibit 
tumor angiogenesis by suppressing the expression of VEGF, 
MMP9, and HIF-1α in a mouse model of Lewis lung cancer 
(Geng et al., 2016). Schisandrin B (Sch B) is the most abundant 
dibenzocyclooctadiene lignan in Schisandra chinensis. Lv et al. 
(2015) found that Sch B could inhibit the migration and invasion 
of A549 cells by decreasing the expressions of HIF-1, VEGF, 
MMP-2, and MMP-9 in vitro. Scutellaria barbata is widely used 
in the treatment of cancer in traditional Chinese medicine. Shiau 
et al. (2014) found that S. barbata could play an antiangiogenic 
role by targeting the HIF-1α signaling pathway and reducing 
the expression of VEGF. Hu et al. (2012) used a mouse model 
of ovarian carcinoma xenograft to study the underlying 
anticancer mechanisms of Zengmian Yiliu granule (ZMYLG), 
a traditional Chinese formula. ZMYLG could downregulate 
the protein expression and mRNA of HIF-1α and VEGF and 
exert antiangiogenic effects on ovarian carcinoma xenografts. 
Triptolide (TPL) is an active ingredient extracted from triptolide 
and widely used in cancer treatment. Li et al. (2018b) found that 
TPL could inhibit angiogenesis by reducing the expression of 
HIF-1α and VEGF in a dose-dependent manner. Protein alpha-
momorcharin (alpha-MMC) is isolated from seeds of the bitter 
gourd Momordica charantia. Pan et al. (2014) showed that alpha-
MMC has significant inhibitory effects on normal and hypoxic 
nasal-pharyngeal cancer cells by blocking HIF-1α signaling such 
as the expression of VEGF and UPR. Baicalein, a type of flavonoid 
isolated from the roots of Scutellaria baicalensis, could suppress 
tumor growth, which is associated with a reduction of HIF-1α 
and VEGF in an orthotopic glioma mouse model (Wang and 
Jiang, 2015) (Figure 4). Table 2 lists important Chinese herbal 
medicines that act on HIF-1 mRNA and/or protein expression.
FIGURE 4 | Herbal medicines promote the activation of the HIF-1 pathway through different targets in ischemic stroke.
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Inhibitors of HIF-1 Transcriptional Activity
So far, several herbal medicines have been shown to inhibit tumor 
angiogenesis through downregulating HIF-1 activation by inhibiting 
its transcriptional activity. Shiau et al. explored the underlying 
mechanisms of S. barbata on regulating HIF-1–dependent 
expression of VEGF. Hypoxia induces angiogenesis by upregulating 
VEGF expression. However, after treatment with S. barbata, the 
expression of VEGF was downregulated in lung cancer cells. In 
addition, S. barbata inhibited the proliferation and migration 
of endothelial cells under a hypoxic environment. S. barbata 
TABLE 2 | Chinese Herbal Medicines and Their Molecular Targets That Are Regulated by the HIF-1 Pathway in Cancer.
Herb Medicine Molecular Target Reference
Inhibitors of HIF-1 mRNA and/or protein expression
Scutellaria barbata HIF-1α protein expression (Shiau et al., 2014)
Antrodia cinnamomea HIF-1α protein expression (Liu et al., 2013)
L. obtusiloba extract HIF-1α protein expression (Freise et al., 2011)
Pien Tze Huang HIF-1α mRNA and protein expression (Chen et al., 2015)
Yi Ai Fang HIF-1α protein expression (Hou et al., 2016)
Changweiqing HIF-1α protein expression (Li et al., 2011)
Erxian decoction HIF-1α protein expression (Yu et al., 2012)
Zengmian Yiliu granule HIF-1α mRNA and protein expression (Hu et al., 2012)
Buyang Huanwu decoction HIF-1α protein expression (Min et al., 2016)
Fraxinellone HIF-1α protein expression (Xing et al., 2018)
Oridonin HIF-1α protein expression (Li C. et al., 2018)
Catalpol HIF-1α protein expression (Zhu et al., 2017)
Pseudolaric acid B HIF-1α protein expression (Wang et al., 2017)
Andrographolide HIF-1α protein expression (Shi et al., 2017)
Baicalein HIF-1α protein expression (Wang and Jiang, 2015)
Berberine HIF-1α protein expression (Fu et al., 2013; Yang et al., 2013; Zhang et al., 2014a; 
Zhang C. et al., 2014; Tsang et al., 2015)
Isoliquiritigenin HIF-1α protein expression (Wang et al., 2013)
alpha-MMC HIF-1α protein expression (Pan et al., 2014)
Total triterpenoid saponins HIF-1α protein expression (Jia et al., 2017)
Licorice HIF-1α protein expression (Park et al., 2016)
Tanshinone IIA HIF-1α protein expression (Fu et al., 2014; Sui et al., 2017)
Triptolide HIF-1α protein expression (Li et al., 2018b)
Ginsenoside Rg3 HIF-1α mRNA and protein expression (Wang et al., 2009; Chen et al., 2010)
20(R)-ginsenoside Rg3 HIF-1α mRNA and protein expression (Geng et al., 2016)
Schizandrin B HIF-1α mRNA and protein expression (Lv et al., 2015)
Rhaponticin HIF-1α mRNA and protein expression (Kim and Ma, 2018)
Cinnamon (CE) HIF-1α mRNA and protein expression (Zhang et al., 2017)
Celastrol HIF-1α mRNA and protein expression (Huang et al., 2011)
Curcumin HIF-1α mRNA and protein expression (Bae et al., 2006; Das and Vinayak, 2014; Li et al., 2018a)
Inhibitors of HIF-1 transcriptional activity
Triptolide HIF-1α transcriptional activity (Zhou et al., 2010)
Scutellaria barbata HIF-1α transcriptional activity (Shiau et al., 2014)
Inhibitors of signal transduction pathways
Methanolic extract mPGES-1–PGE2–HIF-1α (Ranjbarnejad et al., 2017a)
Jianpi-Jiedu formula mTOR–HIF-1α–VEGF (Mao et al., 2016)
Vanillin STAT3–HIF-1α (Park et al., 2017)
Garcinol mPGES-1–PGE2–HIF-1α (Ranjbarnejad et al., 2017b)
Diphyllin mTORC1–HIF-1α–VEGF (Chen H. et al., 2018)
Imperatorin mTOR–p70S6K–4E-BP1, MAPK (Mi et al., 2017)
Shikonin mTOR-p70S6K–4E-BP1 (Li M. et al., 2017)
Tanshinone IIA mTOR-p70S6K-4E-BP1 (Wang X. et al., 2017)
Celastrol mTOR-p70S6K–eIF4E, ERK1/2 (Ma et al., 2014)
5,3’-Dihydroxy-6,7,4’-trimethoxyflavanone 
(DHTMF)
PI3K-Akt-mTOR (Kim et al., 2015)
Ruscogenin PI3K-Akt-mTOR (Hua et al., 2018)
Cryptotanshinone PI3K-Akt-mTOR (Zhang et al., 2018)
PME and PZP PI3K-Akt (Sathya et al., 2010)
Delphinidin PI3K-Akt-mTOR-p70S6K, ERK (Kim et al., 2017)
Gallic acid PTEN–AKT–HIF-1α (He et al., 2016)
Emodin TRAF6–HIF-1α–VEGF (Shi and Zhou, 2018)
Celastrol ROS-Akt-p70S6K (Han et al., 2014)
Triptolide ERK1/2–HIF-1α (Liu H. et al., 2018)
Curcumin DEC1–HIF-1α (Wang X. et al., 2017)
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suppressed the transcriptional activity of HIF-1α and promoted 
the phosphorylation of the upstream signal molecule AKT 
(Shiau et al., 2014). Triptolide is the major active compound in 
traditional Chinese medicine (TCM) herb Tripterygium wilfordii 
Hook F. Triptolide exhibits significant chemotherapeutic 
effects against cancer based on its antiangiogenesis and drug 
resistance circumvention activities. Various biological molecules 
suppressed by triptolide have been identified as its potential 
targets. Triptolide could downregulate the transcriptional activity 
of HIF-1α and further decrease the transcriptional activity of its 
target genes including VEGF (Zhou et al., 2010).
Inhibitors of Signal Transduction Pathways
Several Chinese herbal medicines have been reported to act 
on different signaling pathways to indirectly regulate HIF-1 
activation and exert antiangiogenic effects in cancer treatment. 
Imperatorin is an active natural furocoumarin ingredient from 
Angelica dahurica. Mi et al. (2017) reported that imperatorin 
administration could inhibit tumor growth and tumor 
angiogenesis in vivo and in vitro and downregulate HIF-1α 
activation by targeting the mTOR/p70S6K/4E-BP1 and MAPK 
pathways. 5,3’-Dihydroxy-6,7,4’-trimethoxyflavanone (DHTMF) 
is one of the main ingredients of Vitex rotundifolia. Kim et al. 
(2015) showed that DHTMF could inhibit angiogenesis and 
induce apoptosis by decreasing the expression levels of HIF-1α 
and VEGF via the Akt/mTOR pathway in cancer cells. Kim et al. 
(2017) reported that diphyllin, a natural component of traditional 
Chinese medicine, could regulate the mTORC1/HIF-1α/VEGF 
pathway in the treatment of esophageal cancer (Kim et al., 
2017). Curcumin is an active molecule isolated from the dried 
rhizome of Curcuma longa. Wang D. et al. (2017) found that 
curcumin could downregulate the HIF-1α, VEGF, DEC1, and 
STAT3 signal transduction pathways in the treatment of gastric 
cancer. Garcinol (camboginol) is a natural polyisoprenylated 
benzophenone isolated from dried rind of the Garcinia indica. 
Ranjbarnejad et al. (2017a) found that garcinol could inhibit 
VEGF, MMP2/9, and CXCR4 expression by targeting the 
mPGES-1/PGE2/HIF-1a pathway. Herbal medicines targeting 
signal transduction pathways are reported in Table 2.
ACTIVATION OF HIF-1–DEPENDENT 
ANGIOGENESIS IN ISCHEMIC STROKE
Stroke is one of the major causes of death and long-term disability 
worldwide. About 50% of patients who have suffered from a 
stroke live less than 1 year (Zhang and Chopp, 2009). There are 
two main types of stroke: ischemic and hemorrhagic. Ischemic 
strokes account for about 85% of all strokes, which is caused 
by a sudden halt of blood supply to the brain tissue because of 
ischemia and can result in permanent brain injury (Senior, 2001). 
The thrombotic or embolic occlusion of a cerebral artery will lead 
to irreversible neuronal cell death and further induce serious 
brain injury at the core of the infarct immediately. In addition, 
the secondary injury will result in the expansion of the area of 
brain injury, which can continue for an extended period after the 
first ischemic attack (Chopp and Li, 2002). Thus, reestablishment 
of the functional cerebral microvasculature network will 
improve regional blood supply and promote stroke recovery. 
TABLE 3 | Herbal Medicines and Their Molecular Targets Regulated by the HIF-1 Pathway in Ischemic Stroke.
Herb Medicines Molecular Targets Reference
Activators of HIF-1 mRNA and/or protein expression
Total flavonoid extracts HIF-1α protein expression (He et al., 2018)
MLC901 (herbal extracts) HIF-1α protein expression (Gandin et al., 2016)
Nigella sativa (NS) HIF-1α mRNA expression (Soleimannejad et al., 2017)
Flos Farfarae HIF-1α protein expression (Hwang et al., 2018)
Xue-Fu-Zhu-Yu decoction HIF-1α protein expression (Lee et al., 2011)
Bu Yang Huan Wu decoction HIF-1α mRNA and protein expression (Chen Z. et al., 2018)
Taohong Siwu decoction HIF-1α protein expression (Yen et al., 2014)
Xing-Nao-Jing HIF-1α protein expression (Chen Y. et al., 2018)
Naotai recipe HIF-1α mRNA and protein expression (Chen et al., 2014)
Berberine HIF-1α protein expression (Zhang et al., 2012)
trans-Resveratrol HIF-1α mRNA and protein expression (Agrawal et al., 2013)
Ginsenoside HIF-1α protein expression (Gao et al., 2018)
Xanthohumol HIF-1α protein expression (Yen et al., 2012)
Puerarin HIF-1α protein expression (Chang et al., 2009)
Galangin HIF-1α mRNA expression (Wu et al., 2015)
Activators of signal transduction pathways
Catalpol and puerarin PI3K-AKT-mTOR, ERK (Liu et al., 2017)
Hinokitiol PI3K-AKT (Jayakumar et al., 2013)
Salidroside PI3K-AKT (Wei et al., 2017)
Silibinin AKT-mTOR (Wang et al., 2012)
Andrographolide PI3K-AKT (Chern et al., 2011)
Ginkgolide K (GK) JAK2-STAT3 (Chen M. et al., 2018)
Shengui Sansheng San (SSS) AKT-mTOR (Liu B. et al., 2018)
Huang-Lian-Jie-Du-Tang PI3K-AKT (Zhang et al., 2014b)
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Angiogenesis is a fundamental pathological process in malignant 
tumor growth and development. However, it may also occur as 
an advantageous defense response against hypoxia in ischemic 
stroke by improving blood supply to the brain tissue. Previous 
research has shown that angiogenesis is positively correlated 
to the survival rate of ischemic stroke patients, indicating that 
regulation of the neovascular growth in the ischemic brain could 
be a pivotal target for ischemic stroke treatment. Numerous 
studies have shown that the HIF-1 signaling pathway is likely 
involved in promoting angiogenesis after ischemic stroke in the 
brain (Zhang et al., 2011). As a transcription factor in response 
to hypoxia, HIF-1 activity is increased in brains after ischemic 
attacks. In 1996, it was first reported that both subunit mRNAs of 
HIF-1 were upregulated in the brains of mice or rats when they 
were exposed to a hypoxic environment for 30 to 60 min (Jiang 
et al., 1996). Another study showed that HIF-1α expression was 
dramatically increased in the cerebral cortex of a rat after 60 min 
of recovery from cardiac arrest and remained boosted for more 
than 10 h. In addition, HIF-1α mRNA expression was fortified 
after focal ischemia in rat brain tissue. The increase was detected 
8 h after the onset of ischemia and further elevated at 20 and 25 h 
(Zaman et al., 1999). These results demonstrate that the activity 
of HIF-1 is increased in ischemic brains and that the level of 
HIF-1α expression is heterogeneous. It has been reported that 
the HIF-1–mediated VEGF/Notch1 signaling pathway plays a 
crucial role in the development of angiogenesis in the ischemic 
brain. Apart from VEGF signaling, other complex mechanisms 
may also take part in HIF-1–mediated angiogenesis regulation 
after ischemic stroke. The expressions of angiogenesis–related 
genes such as the endothelin-1 (ET1), adrenomedullin (ADM), 
α1B-adrenergic receptor, nitric oxide synthase, Ang-2, stromal-
derived growth factor-1 (SDF-1), PDGF-B, PlGF, and heme 
oxygenease-1 (HO-1) are also modulated by HIF-1 (Weih 
et al., 1999; Zhang et al., 2007; Yeh et al., 2008). In addition, 
HIF-1 mediated the regulation of collagen prolyl hydroxylase, 
MMPs, and plasminogen activator receptor and inhibitor (PAI) 
expression, which further modulates matrix metabolism and 
vascular maturation in the ischemic brain (Zou et al., 2018).
Because of the potentially pivotal roles in promoting 
angiogenesis by HIF-1 after ischemic stroke, it has been 
recommended that upregulation of HIF-1 activity is a highly 
promising therapeutic strategy for ischemic brain injury. Thus, 
the mechanism of HIF-1–induced angiogenesis in ischemic 
cerebral tissue has drawn much attention and is under extensive 
exploration. Currently, the only FDA-approved therapy for focal 
occlusive ischemia in the brain is the administration of the 
thrombolytic agent tissue plasminogen activator (tPA), which 
may have the risk of bleeding complications (Ohsawa et al., 
2005). Thus, it is imperative to develop additional approaches 
to enhance therapeutic safety in ischemic stroke treatment. In 
recent years, several studies have raised great interest on the 
role of HIF-1 activation in the prognosis of ischemic stroke 
and whether upregulation of HIF-1 could benefit this disease. 
Therapeutic activation of HIF-1 applied before the ischemic 
stress or in the peri-ischemic period may theoretically enhance 
the natural response of angiogenesis in ischemic stroke patients. 
Some strategies have been used successfully on experimental 
activation of HIF-1 in ischemic disease animal models. For 
example, knocking out the central ODD domain will promote the 
activity of HIF-1α. The expression of such an HIF-1α transgenic 
protein in mouse models leads to significant activation of 
HIF-1 transcriptional targets and angiogenesis (Lin-Holderer 
et al., 2016). In addition, those neovessels are not leaky, and the 
intensive vascularity will not induce edema. This result contrasts 
with that of another study of VEGF therapy wherein edema is 
frequently detected and demonstrates that HIF-1 activation 
might keep away from this potential side effect in ischemic 
disease treatment (Ryou et al., 2015). Other studies have tried 
to use genetic therapy targeting to activate HIF-1 in the rabbit 
hind limb ischemia model and rat myocardial infarction model; 
these therapies improved angiogenesis and increased blood flow 
to the ischemic area (Li et al., 2016). Another focus on improving 
HIF-1–induced angiogenesis is suppressing the degradation of 
HIF-1α. For example, a macrophage-derived peptide called PR39 
can interact with the proteasome and inhibit HIF degradation. 
Animal experiments have confirmed that PR39 treatment 
can improve peri-infarct angiogenesis in ischemic cardiac 
tissue (Hao et al., 2009). Besides using proteasome inhibitors, 
overexpression of peptides corresponding to the VHL-binding 
prolyl hydroxylation sites in HIF-1 also inhibits the degradation 
process of HIF-1α and further enhances angiogenesis in ischemic 
tissue. Another combined treatment with transgenic stem cells 
was applied in ischemic stroke rats. Rat bone marrow–derived 
mesenchymal stem cells were transfected with adenovirus 
containing HIF-1α genes with mutations at Asn 803 and Pro 564 
sites, which prevent HIF-1 degradation. The cells with transgenic 
genes were injected into the cerebral artery occlusion of rats. 
After a week, improved angiogenesis and reduced infarction in 
brain tissue were observed; the rats’ ischemic stroke symptoms 
were also relieved (Li C. et al., 2017). HIF prolyl 4-hydroxylase 
domain proteins (PHD) are among the most pivotal inhibitors 
of the HIF-1 pathway. Suppression of the HIF-1 PHD by small 
molecular agents or genetic therapy may also inhibit HIF-1 
degradation and activate the downstream gene’s transcriptional 
activity (Liu Y. et al., 2018). One study verified that PHD ablation 
in neurons improved ischemic stroke recovery in mice through 
endogenous adaptive angiogenesis by activation of the HIF-
VEGF signaling (Mi et al., 2018). In general, the activation 
of HIF-1–dependent angiogenesis may provide therapeutic 
potential in ischemic and hypoxic cerebrovascular diseases. The 
central role of HIF-1 in the modulation of the hypoxia-correlated 
pathway has provided a promising approach for the development 
of novel therapeutic agents for ischemic stroke.
CHINESE MEDICINES MEDIATE 
ANGIOGENIC FACTORS TO PROMOTE 
ANGIOGENESIS BY REGULATING THE 
HIF-1 PATHWAY AFTER ISCHEMIC 
STROKE
Herbal medicines, including herbal formulas, herbal extract, and 
chemical ingredients, have been widely used in the treatment 
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of cardiovascular and cerebrovascular diseases for centuries 
because of reduced side effects (Fan et al., 2017). Previous 
studies indicated that herbal medicines are often used as an 
alternative therapy for prevention, treatment, and rehabilitation 
interventions of ischemic stroke (Table 3). As an important 
component of cerebral angiogenesis in patients with ischemic 
stroke, there has been great attention in developing activators 
targeting the HIF-1 pathway. HIF-1 activation can be induced 
by regulation of one of the following pathways: HIF-1 mRNA 
expression, HIF-1 protein expression, or signal transduction 
pathways. Figure 3 summarizes the treatment of ischemic 
stroke by herbal medicines that regulate HIF-1α to promote 
angiogenesis through the different mechanisms.
Activators of HIF-1 mRNA and/or Protein 
Expression
Several Chinese herbal medicines that target upregulating 
HIF-1 mRNA and/or protein expression have proangiogenic 
effects in ischemic stroke treatment. Ginsenoside, a major active 
ingredient of ginseng, has been demonstrated to be effective in 
the treatment of acute ischemic stroke. Gao et al. (2018) found 
that ginsenoside has therapeutic effects on cerebral ischemia 
and hypoxic injury through the HIF-1α–VEGF pathway in an 
oxygen-glucose deprivation/reperfusion (OGD/R) model of 
neural stem cells (NSCs). Xanthohumol, an ingredient of beer, is 
the principal prenylated flavonoid in hops (Humulus lupulus L). 
Yen et al. reported that xanthohumol-induced neuroprotection is 
associated with many factors such as HIF-1α, iNOS, and TNF-α. 
He et al. established a rat model of transient middle cerebral 
artery occlusion (tMCAO), followed by 24 h of reperfusion 
(Yen et al., 2012). Administration of total flavonoid extracts 
(TFC) could improve neurological deficits, reduce infarct 
volume, and promote angiogenesis by increasing the expression 
of HIF-1α, VEGF, Ang-1, Dll4, Notch1, and CD31 (He et al., 
2018). MLC901, an herbal extract preparation modified from the 
TCM herbal formula, has been proven to have neuroprotective 
and neurorestorative properties in preclinical models of stroke, 
traumatic brain injury, and global cerebral ischemia. Gandin et al. 
(2016) found that 5-week pretreatment with MLC901 in MCAO-
induced cerebral ischemia mouse models could regulate the 
expression of HIF-1α and its downstream targets, such as VEGF, 
Ang-1, and Ang-2. Chen et al. showed that administration of 
TCM formula Bu Yang Huan Wu (BYHW) decoction decreased 
cerebral edema, the neurological deficient score, and brain 
infarct volume in a rat model of cerebral ischemia/reperfusion 
(I/R) injury. Furthermore, BYHW treatment markedly decreased 
the mRNA and protein levels of HIF-1α and VEGF compared 
with those of the model treatment (Chen Z. et al., 2018). Nigella 
sativa (NS) is one of the widely used herbs from the family 
ranunculaceae. Soleimannejad et al. (2017) found that the N. 
sativa extract was associated with increased expression of VEGF 
and HIF-1α, markers of brain angiogenesis after total cerebral 
ischemia in rats. Puerarin, a major isoflavonoid isolated from the 
Chinese medicinal herb Radix puerariae (kudzu root), is widely 
used for treating cardiovascular disease in clinics. Chang et al. 
(2009) used a tMCAO rat model to study the effects of puerarin. 
Administration of puerarin inhibited the expression of HIF-1α, 
TNF-α, iNOS, caspase-3, and many factors, and it may be an ideal 
therapeutic measure after ischemia-reperfusion brain injury. 
Xue-Fu-Zhu-Yu decoction (XFZYD) is a traditional Chinese 
medicine formula widely used in cardiovascular diseases. Lee 
et al. found that XFZYD administration slightly reduced infarct 
volume compared with that of solvent-treated rats. However, the 
combination of XFZYD and recombinant tissue plasminogen 
activator (rt-PA) significantly reduced the infarct volume in 
cerebral ischemic areas. In addition, rt-PA administration 
significantly reduced the expression of TNF-α and iNOS but 
did not decrease the expression of HIF-1α or caspase-3, whereas 
XFZYD administration significantly reduced the expression of 
all these proteins in the ischemic region. In addition, XFZYD 
administration significantly enhanced the reduction of rt-pa–
mediated TNF-α, iNOS, HIF-1α, and active caspase-3 expression 
(Lee et al., 2011). Galangin, a commonly used antioxidant, is a 
natural flavonoid derived from the rhizome of Alpina officinarum 
Hance. Wu et al. (2015) showed that galangin could promote 
angiogenesis and vascular remodeling to improve neurological 
function scores and the cerebral infarct area by upregulating the 
Wnt/β-catenin and HIF-1α/VEGF signaling pathway in a MCAO 
rat model. Herbal medicines targeting HIF-1 mRNA and/or 
protein expression are provided in Table 2.
Activators of Signal Transduction 
Pathways
Several studies have shown that Chinese herbal medicines can 
also target different signal transduction pathways to upregulate 
HIF-1-induced angiogenesis. Huang-Lian-Jie-Du-Tang (HLJDT) 
is a classical heat-clearing and detoxicating formula of traditional 
Chinese medicine. Zhang et al. found that HLJDT preconditioning 
in the MCAO rat model could decrease the cerebral infarction 
volume, neurological deficient score, and cerebral water content. 
In addition, HLJDT preconditioning in cerebral cortical neurons 
in vitro under oxygen and glucose deprivation (OGD) could 
increase HIF-1α, VEGF, and erythropoietin (EPO) expression 
levels and activation of the PI3K/AKT signaling pathway (Zhang 
et al., 2014b). Shengui Sansheng San (SSS), a traditional Chinese 
herbal formula, has been used for stroke for more than 300 years. 
B. Liu et al. (2018) showed that SSS could activate AKT/mTOR/
HIF-1α and ERK1/2 signals to facilitate VEGF production, 
resulting in angiogenesis after stroke in the rat MCAO model. 
Ginkgolide K (GK) is an extract isolated from the leaves of 
Ginkgo biloba. Chen et al. have used a tMCAO mouse model 
to verify the pharmacological properties of GK. GK treatment 
could significantly increase the expressions of HIF-1α and 
VEGF in the tMCAO model. In the OGD/R model of bEnd.3 
cells, GK-induced upregulation of HIF-1α and VEGF could 
be  eliminated by JAK2/STAT3 inhibitor AG490 (Chen et al., 
2018). Andrographolide is a bicyclic diterpenoid lactone from 
the leaves of Andrographis paniculata (Acanthaceae). Chen et al. 
suggested that andrographolide could ameliorate brain injury 
in ischemic stroke by PI3K/AKT–dependent activation of the 
NF-κB and further activation of HIF-1α pathways in vivo and 
in vitro (Chern et al., 2011). As a conclusion, the herbal medicines 
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targeting HIF-1 signal transduction pathways are provided in 
Table 2.
CONCLUSIONS AND FUTURE 
DIRECTIONS
HIF-1–induced angiogenesis has been involved in numerous 
pathological conditions, and it may be harmful or beneficial 
depending on the types of specific disease. Since the 1970s, the 
exploration on angiogenesis has sparked hopes in providing 
novel therapeutic approaches in multiple diseases with high 
mortality rates, such as cancers and ischemic stroke. Depending 
on different types of diseases and the expected treatment effects, 
angiogenesis-targeted therapies have different approaches. 
Generally, the clinical application of angiogenesis can be 
classified into two different strategies: antiangiogenesis (cancer) 
and proangiogenesis (ischemic stroke). The induction of 
angiogenesis for therapeutic purposes in ischemic stroke can be 
directly stimulated by various angiogenic factors, such as PlGF, 
VEGF, PDGF, and FGF, some of which have been applied in 
preclinical and clinical studies. However, treatments only using 
proangiogenic factors to induce angiogenesis were proven to be 
insufficient in ischemic disease; thus, novel treatments that can 
stabilize neovascularization with high-efficiency are required for 
better therapeutic effects. Therefore, HIF-1–induced angiogenesis 
may be a promising strategy for ischemic cerebrovascular 
disease. HIF-1 activation in ischemic cerebrovascular disease 
leads to a more mature and stable vascular formation compared 
with that of traditional proangiogenic factor therapy, wherein 
neovascularization tends to be leaky. Instead of proangiogenesis 
in ischemic stroke therapy, cancer treatments are based on 
suppression of angiogenesis for inhibiting tumor growth and 
metastasis. Current therapies are focused on suppressing VEGF 
activity, such as sunitinib (VEGFR2 inhibitor) and bevacizumab 
(VEGF inhibitor) target therapy. Because of the pivotal role of 
the HIF-1 pathway in modulating the activation of various 
proangiogenic factors in cancers, HIF-1 has been considered 
as a promising target for developing novel anticancer agents. 
Suppression of HIF-1–dependent angiogenesis involves the 
modulation of HIF-1 activity by regulating HIF-1α transcription 
and protein translation, HIF-1α DNA binding, HIF-1α and 
HIF-1β dimerization, and HIF-1 degradation. Considering 
the profound impact of HIF-1 on cancer progression and the 
unsatisfactory efficacy of current treatment protocols, several 
clinical trials are being conducted with potential antiangiogenesis 
agents that involve protein degradation, downregulation, or 
inactivation of HIF-1. It is noteworthy that, within a single herb 
concoction, sometimes we can find both inhibitors and activators 
of HIF-1, which will complicate the use of herbal medicines 
under clinical conditions. For example, ginsenoside Rg3 and 
ginsenoside Rg1 are both natural triterpenoid saponins extracted 
from red ginseng. Previous studies showed that ginsenoside Rg3 
could inhibit tumor angiogenesis by decreasing the expression of 
HIF-1 in various cancers, whereas ginsenoside Rg1 might inhibit 
myocardial ischemia and reperfusion injury by activating HIF-1 
(Chen et al., 2010; Yuan et al., 2019).
With a long history of more than 2,000 years of clinical 
use, Chinese herbal medicine is emerging as a complementary 
and alternative choice for its multitargeted, multileveled, and 
coordinated intervention effects against complex disorders, such 
as cancer and ischemic stroke. Research results from many in 
vitro and in vivo studies have demonstrated that several Chinese 
herbal formulations, herbs, or herbal compounds can induce 
or inhibit angiogenesis through multiple cellular mechanisms. 
Numerous preclinical studies have provided supportive evidence 
for using Chinese herbal medicines as a novel antiangiogenesis 
therapy for cancer or proangiogenesis therapy for ischemic stroke 
by targeting the HIF-1 pathway. However, the overall scientific 
evidence to back the application of Chinese herbal medicines for 
the management of cancer and ischemic stroke remains limited, 
and the results of these researches are sometimes contradictory 
and inconclusive. The underlying reasons for these inconsistencies 
include the complex chemical and pharmacological properties 
of Chinese herbal medicines and the interactions between the 
multiple bioactive ingredients of Chinese herbal medicines. 
More researches are needed to gain a better understanding of 
the dual effects of Chinese herbal medicines on angiogenesis in 
cancer and ischemic stroke treatment. In addition, despite the 
long history of Chinese herbal medicines in the treatment of 
cancer and ischemic stroke, well-controlled clinical studies with 
herbal medicinal products used for treating these diseases are 
still limited. More rigorously designed, controlled, randomized, 
international, multicenter clinical trials are urgently required for 
further validating Chinese herbal medicine efficacy in cancer 
and ischemic stroke treatment. Finally, as a double-edged sword, 
the important role of HIF-1 in angiogenesis should be considered 
as a promising target for treating cancer or ischemic stroke. 
The possible side effects and potential risk of angiogenesis-
related complications by Chinese herbal medicines should 
also be considered when applying the HIF-1 target strategy for 
management of ischemic stroke and cancer.
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